Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GMED · against 588 other Healthcare companies listed in US-listed
Ranked #59 of 589 · scores higher than 90% of peers
Bars: peers in each 10-point band of the valuation score31 peers with a valuation score of 70–79, including GMED · Click a bar to see the companies
Mainly thanks to its free cash flow yield, EBITDA yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | GMED | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | 4.9% | -4.3% | 89% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 9.9% | -0.8% | 86% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 7.0% | -2.3% | 89% | 20% | |
| Book yieldHigher is better · 587 reported | 44.6% | 25.9% | 70% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 52 | 2.3B USD | 80 | 52 | |
| 56 | 320M USD | 79 | 44 | |
| 56 | 418M USD | 79 | 74 | |
| 58 | 393M USD | 78 | 61 | |
| 59 | 10.7B USD | 77 | 78 | |
| 60 | 89.7B USD | 76 | 50 | |
| 60 | 528M USD | 76 | 58 | |
| 62 | 2.3B USD | 75 | 74 | |
| 62 | 38.9B USD | 75 | 56 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score